Genmab — Marts 2021
-
wtf - normal volumen, afmålt kursudvikling, marginal stigning i et marked med relativ stor rentestining https://www.investing.com/rates-bonds/u.s.-10-year-bond-yield
-
er vi ved at se en normalisering?
-
Kursmål Ligger i debatten https://www.proinvestor.com/boards/89730#postdiv91872
-
-
God morgen.
-
Stoxx: Europæisk health care peger igen nedad
https://www.proinvestor.com/investornyt/673078/stoxx-europaeisk-health-care-peger-igen-nedad -
-
@Sukkeralf. Lidt overraskende at høre nyt om dette studie nu. Troede at det var gået i glemmebogen. ( begravet i stilhed ) ;-). Men vel positivt at de fortsætter. - måske nye data understøtter en fortsættelse. ??
-
God morgen.
-
Langers Skarpe: Investorerne forlader tech, health care og biotek
https://www.proinvestor.com/investornyt/673079/langers-skarpe-investorerne-forlader-tech-health-care-og-biotek -
BMS har 6 aktive studier med nivolumab og IL8. High levels of serum IL-8 are associated with a poor prognosis in various tumors (Sanmamed, MF, et al. Clin Cancer Res. 2014;20:5697-5707), such as melanoma, non-squamous small cell lung cancer (NSCLC), and renal cell carcinoma, and decreases in serum IL-8 levels have been suggested to be associated with response to anti–PD-(L)1 therapy with nivolumab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind